Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pseudocirrhosis due to liver metastasis from lung adenocarcinoma.
Shijubou N, Sumi T, Keira Y, Shiraishi H, Nagahisa Y, Matsuura K, Sekikawa M, Yamada Y, Nakata H, Chiba H. Shijubou N, et al. Among authors: sekikawa m. Thorac Cancer. 2021 Sep;12(17):2407-2410. doi: 10.1111/1759-7714.14084. Epub 2021 Jul 17. Thorac Cancer. 2021. PMID: 34273140 Free PMC article.
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S. Ikezawa Y, et al. Among authors: sekikawa m. Cancer Sci. 2022 Jun;113(6):2109-2117. doi: 10.1111/cas.15361. Epub 2022 Apr 15. Cancer Sci. 2022. PMID: 35377496 Free PMC article.
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.
Sumi T, Koshshino Y, Sekikawa M, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Watanabe H, Michimata H, Nagayama D, Tanaka Y, Yamada Y, Chiba H. Sumi T, et al. Among authors: sekikawa m. Invest New Drugs. 2022 Dec;40(6):1298-1305. doi: 10.1007/s10637-022-01310-x. Epub 2022 Oct 13. Invest New Drugs. 2022. PMID: 36227514
Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second-line chemotherapy in patients with small cell lung cancer.
Sekikawa M, Murakami H, Morita M, Doshita K, Miura K, Kodama H, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Kenmotsu H, Naito T, Chiba H, Takahashi T. Sekikawa M, et al. Thorac Cancer. 2023 Dec;14(35):3475-3482. doi: 10.1111/1759-7714.15140. Epub 2023 Oct 24. Thorac Cancer. 2023. PMID: 37873674 Free PMC article.
Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Suzuki K, Ikeda T, Michimata H, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H. Sumi T, et al. Among authors: sekikawa m. Thorac Cancer. 2024 Jul;15(20):1572-1581. doi: 10.1111/1759-7714.15385. Epub 2024 Jun 3. Thorac Cancer. 2024. PMID: 38828610 Free PMC article.
89 results